Literature DB >> 28812384

Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study.

Juan P Cata1,2, Acsa M Zavala1, Antoinette Van Meter1, Uduak U Williams1, Jose Soliz1, Mike Hernandez3, Pascal Owusu-Agyemang1,2.   

Abstract

BACKGROUND: Acute kidney injury (AKI) is a postoperative complication associated with significant morbidity and mortality. The incidence and risks factors for AKI after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) have not been fully studied. The purpose of this study was to identify perioperative risk factors predictive of AKI after CRS-HIPEC.
METHODS: This retrospective study collected demographic, tumour-related, intraoperative and postoperative data from 475 patients who underwent CRS-HIPECs. AKI was defined using the acute kidney injury network criteria and calculated on postoperative days 1, 2, 3, 7 and day of hospital discharge. We conducted univariate and multivariate analyses to assess the association between variables of interest and AKI. A p value of <0.05 was considered statistically significant.
RESULTS: The incidence of AKI was 21.3%. The multivariate analysis identified six predictor factors independently associated with the development of AKI (OR: [95%CI]); age: 1.16 (1.05-1.29, p < 0.005), BMI (overweight: 1.97 [1.00-3.88], p = 0.05) and obesity: 2.88 (1.47-5.63), p < 0.002)), preoperative pregabalin: 3.04 (1.71-5.39, p < 0.037), platinum-based infusion: 3.04 (1.71-5.39, p < 0.001) and EBL: 1.77 (1.27-2.47, p < 0.001). Splenectomy had a protective effect (OR: 0.44 (0.25-0.76, p < 0.003).
CONCLUSIONS: Our study demonstrates that the incidence of AKI is high. While other studies have reported that AKI is associated with platinum-based infusion, age and obesity, we report for the first time a negative association between pregabalin use and AKI. More studies are needed to confirm our results.

Entities:  

Keywords:  Kidney injury; chemotherapy; hyperthermia; surgery

Mesh:

Year:  2017        PMID: 28812384     DOI: 10.1080/02656736.2017.1368096

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  10 in total

1.  Impact of Enhanced Recovery After Surgery on Postoperative Outcomes for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Bradley White; Fadi Dahdaleh; Samer A Naffouje; Neerav Kothari; Jessica Berg; Wendy Wiemann; George I Salti
Journal:  Ann Surg Oncol       Date:  2021-01-19       Impact factor: 5.344

2.  Sodium thiosulfate during cisplatin-based hyperthermic intraperitoneal chemotherapy is associated with transient hypernatraemia without clinical sequelae.

Authors:  Anais Alonso; Winston Liauw; Helen Kennedy; Nayef A Alzahrani; David L Morris
Journal:  Pleura Peritoneum       Date:  2022-05-02

3.  Association of intraoperative gross hematuria with acute kidney injury after cytoreductive surgery.

Authors:  Yumi Mitani; Yohei Arai; Yoshimasa Gohda; Hideaki Yano; Isao Kondo; Emi Sakamoto; Daisuke Katagiri; Fumihiko Hinoshita
Journal:  Pleura Peritoneum       Date:  2022-02-18

4.  Routine prophylactic ureteral stenting before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Safety and usefulness from a single-center experience.

Authors:  Paola Fugazzola; Federico Coccolini; Matteo Tomasoni; Enrico Cicuttin; Maria Grazia Sibilla; Francesca Gubbiotti; Andrea Lippi; Mario Improta; Giulia Montori; Marco Ceresoli; Michele Pisano; Luca Ansaloni
Journal:  Turk J Urol       Date:  2019-09-01

5.  Acute kidney injury increases the rate of major morbidities in cytoreductive surgery and HIPEC.

Authors:  Samer A Naffouje; Kiara A Tulla; Regina Chorley; Nancy Armstrong; George I Salti
Journal:  Ann Med Surg (Lond)       Date:  2018-09-26

6.  Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).

Authors:  Sohan Lal Solanki; Sudipta Mukherjee; Vandana Agarwal; Raghu S Thota; Kalpana Balakrishnan; Shagun Bhatia Shah; Neha Desai; Rakesh Garg; Reshma P Ambulkar; Nitin Madhukar Bhorkar; Viplab Patro; Snita Sinukumar; Meenakshi V Venketeswaran; Malini P Joshi; Rajesh Holalu Chikkalingegowda; Vijaya Gottumukkala; Pascal Owusu-Agyemang; Avanish P Saklani; Sanket Sharad Mehta; Ramakrishnan Ayloor Seshadri; John C Bell; Sushma Bhatnagar; Jigeeshu V Divatia
Journal:  Indian J Anaesth       Date:  2019-12-11

7.  Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Matilde Zaballos; Mercedes Power; María Iluminada Canal-Alonso; María Ángeles González-Nicolás; Wenceslao Vasquez-Jimenez; Pablo Lozano-Lominchar; Pilar Cabrerizo-Torrente; Natividad Palencia-García; Susana Gago-Quiroga; María Dolores Ginel-Feito; Consuelo Jiménez; Alberto Lázaro; Luis González-Bayón
Journal:  Int J Mol Sci       Date:  2021-01-27       Impact factor: 5.923

8.  Reflex Anuria: A Complication of Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Mohamed Fayed; Gargi Banerjee; Danni Feng; Irene Chen
Journal:  Cureus       Date:  2021-12-08

9.  HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model.

Authors:  Lukas F Liesenfeld; Benedikt Wagner; H Christian Hillebrecht; Maik Brune; Christoph Eckert; Johannes Klose; Thomas Schmidt; Markus W Büchler; Martin Schneider
Journal:  Ann Surg Oncol       Date:  2021-07-14       Impact factor: 5.344

10.  Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study.

Authors:  Annika Kurreck; Felix Gronau; Miguel Enrique Alberto Vilchez; Wiltrud Abels; Philipp Enghard; Andreas Brandl; Roland Francis; Bettina Föhre; Christian Lojewski; Johann Pratschke; Peter Thuss-Patience; Dominik Modest; Beate Rau; Linda Feldbrügge
Journal:  Ann Surg Oncol       Date:  2021-08-04       Impact factor: 5.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.